O-030Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. (20th June 2018) - Hochster, H; Catalano, Paul J; O'Dwyer, Peter J; Mitchell, Edith P; Jill Cohen, Deirdre; Andrew Faller, Bryan; Kortmansky, Jeremy S; Mehta Kircher, Sheetal; Lacy, Jill; Lenz, Heinz-Josef; Verma, Udit N; Bowen Benson III, Al; et al.